{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:36:19Z","timestamp":1790487379511,"version":"4.1.0"},"reference-count":16,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The coadministration of the combined meningococcal serogroup C conjugate (MCC)\/\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            type b (Hib) vaccine with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella (MMR) vaccine at 12 months of age was investigated to assess the safety and immunogenicity of this regimen compared with separate administration of the conjugate vaccines. Children were randomized to receive MCC\/Hib vaccine alone followed 1 month later by PCV7 with MMR vaccine or to receive all three vaccines concomitantly. Immunogenicity endpoints were MCC serum bactericidal antibody (SBA) titers of \u22658, Hib-polyribosylribitol phosphate (PRP) IgG antibody concentrations of \u22650.15 \u03bcg\/ml, PCV serotype-specific IgG concentrations of \u22650.35 \u03bcg\/ml, measles and mumps IgG concentrations of &gt;120 arbitrary units (AU)\/ml, and rubella IgG concentrations of \u226511 AU\/ml. For safety assessment, the proportions of children with erythema, swelling, or tenderness at site of injection or fever or other systemic symptoms for 7 days after immunization were compared between regimens. No adverse consequences for either safety or immunogenicity were demonstrated when MCC\/Hib vaccine was given concomitantly with PCV and MMR vaccine at 12 months of age or separately at 12 and 13 months of age. Any small differences in immunogenicity were largely in the direction of a higher response when all three vaccines were given concomitantly. For systemic symptoms, there was no evidence of an additive effect; rather, any differences between schedules showed benefit from the concomitant administration of all three vaccines, such as lower overall proportions with postvaccination fevers. The United Kingdom infant immunization schedule now recommends that these three vaccines may be offered at one visit at between 12 and 13 months of age.\n          <\/jats:p>","DOI":"10.1128\/cvi.00516-10","type":"journal-article","created":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T01:53:58Z","timestamp":1293674038000},"page":"367-372","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Safety and Immunogenicity of Coadministering a Combined Meningococcal Serogroup C and\n            <i>Haemophilus influenzae<\/i>\n            Type b Conjugate Vaccine with 7-Valent Pneumococcal Conjugate Vaccine and Measles, Mumps, and Rubella Vaccine at 12 Months of Age"],"prefix":"10.1128","volume":"18","author":[{"given":"Elizabeth","family":"Miller","sequence":"first","affiliation":[{"name":"Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[{"name":"Statistics and Modelling Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Waight","sequence":"additional","affiliation":[{"name":"Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Findlow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Ashton","sequence":"additional","affiliation":[{"name":"Immunobiology Unit, Institute of Child Health, University College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"England","sequence":"additional","affiliation":[{"name":"Immunoassay Laboratory, Health Protection Agency Microbiology Services Porton, Salisbury SP4 0JG, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Stanford","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Matheson","sequence":"additional","affiliation":[{"name":"Immunoassay Laboratory, Health Protection Agency Microbiology Services Porton, Salisbury SP4 0JG, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Southern","sequence":"additional","affiliation":[{"name":"Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sheasby","sequence":"additional","affiliation":[{"name":"Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldblatt","sequence":"additional","affiliation":[{"name":"Immunobiology Unit, Institute of Child Health, University College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom"},{"name":"University of Manchester, Inflammation Sciences Research Group, School of Translational Medicine, Stopford Building, Manchester M13 9PL, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00384-09"},{"key":"e_1_3_2_3_2","unstructured":"Important changes to the childhood immunisation programme. 2006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Vaccinations at 12 and 13 months of age. 2010","DOI":"10.1016\/S1369-7021(10)70029-8"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.diagmicrobio.2010.03.008","volume":"67","year":"2010","unstructured":"Dhiman, N., et al. 2010. Detection of IgG-class antibodies to measles, mumps, rubella, and varicella-zoster virus using a multiplex bead immunoassay. Diagn. Microbiol. Infect. Dis. 67:346-349.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","volume":"29","year":"2010","unstructured":"D\u00edez-Domingo J., et al. 2010. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr. Infect. Dis. J. 29:148-152.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/INF.0b013e3181c67f04","volume":"29","year":"2010","unstructured":"Goldblatt, D., et al. 2010. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr. Infect. Dis. J. 29:401-405.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1086\/314901","volume":"180","year":"1999","unstructured":"Goldblatt, D., P. Richmond, E. Millard, C. Thornton, and E. Miller. 1999. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J. Infect. Dis. 180:538-541.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1099\/00222615-25-4-279","volume":"25","year":"1988","unstructured":"Melville-Smith, M., and A. Balfour. 1988. Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test. J. Med. Microbiol. 25:279-283.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","volume":"11","year":"1983","unstructured":"Melville-Smith, M. E., V. A. Seagroatt, and J. T. Watkins. 1983. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J. Biol. Standard. 11:137-144.","journal-title":"J. Biol. Standard."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/adc.88.3.222","volume":"88","year":"2003","unstructured":"Miller, E., N. Andrews, P. Waight, and B. Taylor. 2003. Bacterial infections, immune overload, and MMR vaccine. Measles, mumps, and rubella. Arch. Dis. Child. 88:222-223.","journal-title":"Measles, mumps, and rubella. Arch. Dis. Child."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/adc.2007.136036","volume":"93","year":"2008","unstructured":"Pace, D., et al. 2008. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch. Dis. Child. 93:963-970.","journal-title":"Arch. Dis. Child."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(90)90264-V"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00420-08"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.vaccine.2008.12.038","volume":"27","year":"2009","unstructured":"Stowe, J., N. Andrews, B. Taylor, and E. Miller. 2009. No evidence of an increase of bacterial or viral infections following measles, mumps and rubella vaccine. Vaccine 27:1422-1425.","journal-title":"Vaccine"},{"key":"e_1_3_2_17_2","unstructured":"World Health Organization Pneumococcal Serology Reference Laboratories and Department of Pathology University of Alabama at Birmingham. 2007. Training manual for enzyme linked immunosorbent assay for quantification of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). World Health Organization Pneumococcal Serology Reference Laboratories at the Institute of Child Health University College London London England and Department of Pathology University of Alabama Birmingham AL. http:\/\/www.vaccine.uab.edu\/ELISA%20Protocol.pdf."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00516-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00516-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:45:11Z","timestamp":1627591511000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00516-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1128\/CVI.00516-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00516-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"2010-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}